NEW YORK (GenomeWeb) – Goldman Sachs today upgraded shares of Alere to a Buy rating, but downgraded Quest Diagnostics' shares to Neutral. 

In a research note, analyst Isaac Ro upgraded Alere from a previous Neutral rating and said that he believes that Alere's new management has brought focus to the firm's new products, streamlined its cost structure, and reduced its debt. As a result, he anticipates revenues to grow about 6 percent between the firm's fiscal years 2015 and 2018, and EPS to grow 17 percent during the same period. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.

Nobel laureate Günter Blobel has died at 81, the New York Times reports.

In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.